Prosecution Insights
Last updated: April 19, 2026

Examiner: GEMBEH, SHIRLEY V

Tech Center 1600 • Art Units: 1615 1618 1628

This examiner grants 63% of resolved cases

Performance Statistics

63.1%
Allow Rate
+3.1% vs TC avg
1648
Total Applications
+33.6%
Interview Lift
977
Avg Prosecution Days
Based on 1606 resolved cases, 2023–2026

Rejection Statute Breakdown

0.9%
§101 Eligibility
18.2%
§102 Novelty
39.0%
§103 Obviousness
15.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18503027 Anhydrous Sodium Thiosulfate and Formulations Thereof Non-Final OA Fennec Pharmaceuticals Inc.
18044357 METHODS AND MATERIALS FOR EMBOLIZATION Final Rejection BOSTON SCIENTIFIC SCIMED, INC.
18192479 MINIMIZING SKIN IRRITATION DUE TO SKIN ADHESION PATCHES Final Rejection Medtronic MiniMed, Inc.
18626281 COMPOSITIONS AND METHODS FOR ALTERING THE COLOR OF HAIR Non-Final OA L'OREAL
18245712 THERAPEUTIC AGENT FOR MALIGNANT MESOTHELIOMA AND METHOD FOR SELECTING PATIENT HAVING MALIGNANT MESOTHELIOMA Final Rejection National University Corporation Tokai National Higher Education and Research System
17760083 COMPOSITIONS AND METHODS FOR IN SITU-FORMING GELS FOR WOUND HEALING AND TISSUE REGENERATION Final Rejection The United States Government as Represented by The Department of Veterans Affairs
18537567 STARCH BASED NANOPARTICLES FOR PLANT DELIVERY Non-Final OA MCMASTER UNIVERSITY
18026847 AN ANTIPERSPIRANT COMPOSITION Final Rejection Conopco, Inc., d/b/a UNILEVER
18260089 NANOCONE CLUSTERS SUITABLE FOR USE AS HISTOTRIPSY AGENT Final Rejection ISTANBUL MEDIPOL UNIVERSITESI TEKNOLOJI TRANSFER OFISI ANONIM SIRKETI
18548645 NOVEL COMPOSITION Non-Final OA RECKITT BENCKISER HEALTH LIMITED
18672743 COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON’S DISEASE, PARKINSON’S DISEASE WITH DEMENTIA, DEMENTIA WITH LEWY BODIES, AND MULTIPLE SYSTEM ATROPHY Non-Final OA Stealth BioTherapeutics Inc.
18707432 EXTRACELLULAR VESICLES OR COMPOSITION THEREOF FOR USE AS A MEDICAMENT, SUCH AS FOR THE TREATMENT OF OCULAR SURFACE DISORDERS Non-Final OA FONDATION A DE ROTHSCHILD
18699871 AN INJECTABLE POLYHYDROXYALKANOATE MICROSPHERE AND A PREPARATION METHOD THEREOF Non-Final OA BEIJING JOYINERA BIOMATERIAL TECHNOLOGY CO., LTD.
18696708 FACIAL AND BODY SUNSCREEN COMPOSITION Non-Final OA Love Sun Body IP Holdings LLC
18121256 OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT Final Rejection OCULAR THERAPEUTIX, INC.
18691680 A FILM-FORMING COMPOSITION COMPRISING PECTIN Non-Final OA INTERNATIONAL N&H USA, INC.
18685324 A PHOTOPROTECTIVE PERSONAL CARE COMPOSITION Non-Final OA Conopeo, Inc, d/b/a UNILEVER
18408745 DUAL-PURPOSE ANALGESIC COSMETIC COMPOSITION Non-Final OA Coverology Inc.
17617853 METHOD FOR CHARGING A CONTAINER FOR USE WITH A MEDICATION DELIVERY APPARATUS, CONTAINER FOR SUCH AN APPARATUS AND METHOD FOR TREATING A PATIENT Final Rejection Mexichem Fluor S.A. de C.V.
18239131 ALZHEIMER'S DISEASE TREATMENT AND METHODS Non-Final OA CARBON 60 (ZHEJIANG) PHARMACEUTICAL TECHNOLOGY CO., LTD.
18455233 RADIOACTIVE GLASS MICROSPHERES FOR EMBOLIZATION, PREPARATION METHOD AND APPLICATION THEREOF Non-Final OA Sun Yat-sen University Cancer Center (The Affiliated Cancer Hospital of Sun Yat-sen University,
18246315 MULTI-COMPONENT SYSTEM Final Rejection Sphera Technology GmbH
18181494 COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING Non-Final OA Shanghai Lumosa Therapeutics Co., Ltd.
17904530 Multicompartement hydrogel fibre their preparation and uses thereof Final Rejection Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4TEC
17874994 DIETARY FIBER COMPOSITIONS Non-Final OA G&S Laboratories, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month